The Valley Spectrum
  • Login
  • Top Stories
  • J&K
  • National
  • International
  • Business
  • Editorial
  • Health
  • Sports
  • More
    • Entertainment
    • Technology
No Result
View All Result
  • Top Stories
  • J&K
  • National
  • International
  • Business
  • Editorial
  • Health
  • Sports
  • More
    • Entertainment
    • Technology
No Result
View All Result
The Valley Spectrum
No Result
View All Result

SEC meeting on full market approval for Covishield, Covaxin today: Report

by VS Desk
January 16, 2022
in Business
0
SEC meeting on full market approval for Covishield, Covaxin today: Report
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

New Delhi: Drugs Controller General of India (DCGI)’s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said. SII had applied for market approval for the Covishield vaccine in December 2021 and Bharat Biotech has also applied for the same 10 days ago. Further, Bharat Biotech has informed that Covaxin is now a universal vaccine for adults and children. “Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed,” it said.

However, both Covaxin and Covishield are currently authorized for emergency use only.

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) met on January 1 and January 2, 2021, and made recommendations in respect of the proposal for Restricted Emergency Approval of COVID-19 virus vaccines of Serum Institute of India and Bharat Biotech.

The SEC consists of domain knowledge experts from the fields of pulmonology, immunology, microbiology, pharmacology, pediatrics, internal medicine, etc.

It had reviewed the data on the safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in an emergency situation in the public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue.

SII and Bharat Biotech vaccines have to be administered in two doses. All three vaccines have to be stored at 2-8 degrees Celsius.After adequate examination, CDSCO had decided to accept the recommendations of the Expert Committee and accordingly, SII’s Covishied and Bharat Biotech’s Covaxin were approved for restricted use in an emergency situation.

VS Desk

VS Desk

Next Post
Ola Electric to open final payment window for scooter buyers on Jan 21

Ola Electric to open final payment window for scooter buyers on Jan 21

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

S-400 Missile Systems: Deployment Of First Regiment To Be Completed Next Month

S-400 Missile Systems: Deployment Of First Regiment To Be Completed Next Month

1 year ago
Centre Extends Tenures Of Secretaries Of Defence And Home, IB And RAW Chiefs

Centre Extends Tenures Of Secretaries Of Defence And Home, IB And RAW Chiefs

2 years ago

Popular News

Plugin Install : Popular Post Widget need JNews - View Counter to be installed

Connect with us

  • About
  • Advertise
  • Careers
  • Contact
Call us: +1 234 JEG THEME

Copyright © 2021 The Valley Spectrum. The Valley Spectrum not responsible for the content of external sites.

No Result
View All Result
  • Top Stories
  • J&K
  • National
  • International
  • Business
  • Editorial
  • Health
  • Sports
  • More
    • Entertainment
    • Technology

Copyright © 2021 The Valley Spectrum. The Valley Spectrum not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In